CSPC Pharmaceutical Group revenue and financials
$10.00Change from previous close: +1.47%Absolute change: +$0.14
In the fiscal year ended December 2025, CSPC Pharmaceutical Group reported revenue of ¥26.01B (−10.35% year over year). Net income was ¥3.88B, a net margin of 14.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −10.35%
- 2025 vs 2024
- Net income growth
- −10.30%
- 2025 vs 2024
- Net margin
- 14.9%
- 2024: 14.9%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 46,698 | 44,389 | 46,282 | 41,770 | — |
| Current assets | 22,251 | 21,888 | 26,745 | 23,957 | — |
| Cash and equivalents | 6,090 | 6,777 | 12,015 | 10,298 | — |
| Short-term investments | 2,776 | 1,473 | 1,077 | 3,575 | — |
| Inventory | 3,091 | 3,130 | 3,139 | 2,555 | — |
| Net property, plant and equipment | 14,046 | 13,079 | 12,262 | 11,773 | — |
| Goodwill | 235 | 235 | 235 | 235 | — |
| Other intangible assets | 2,775 | 2,610 | 2,199 | 1,908 | — |
| Long-term investments | 1,466 | 1,527 | 1,468 | 1,395 | — |
| Current liabilities | 10,178 | 9,634 | 10,183 | 8,958 | — |
| Accounts payable | 2,976 | 2,613 | 2,842 | 2,010 | — |
| Long-term debt | — | — | 0.0 | 29.0 | 0.0 |
| Total debt | 641 | 507 | 707 | 583 | — |
| Total liabilities | 12,148 | 10,523 | 11,264 | 10,128 | — |
| Total equity (incl. minority) | 34,550 | 33,866 | 35,018 | 31,642 | — |
| Retained earnings | 24,475 | 23,344 | 24,035 | 21,136 | — |
| Minority interest | 1,372 | 1,602 | 1,815 | 1,444 | — |